Lbp Am Sa Reduces Stock Position in Merck & Co., Inc. $MRK

Lbp Am Sa cut its stake in Merck & Co., Inc. (NYSE:MRK) by 2.5% in the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 335,911 shares of the company’s stock after selling 8,513 shares during the period. Lbp Am Sa’s holdings in Merck & Co., Inc. were worth $26,591,000 at the end of the most recent reporting period.

A number of other hedge funds also recently added to or reduced their stakes in the stock. Little House Capital LLC increased its stake in shares of Merck & Co., Inc. by 1.2% during the 2nd quarter. Little House Capital LLC now owns 25,236 shares of the company’s stock worth $1,998,000 after purchasing an additional 308 shares in the last quarter. Semus Wealth Partners LLC increased its stake in shares of Merck & Co., Inc. by 8.2% during the 1st quarter. Semus Wealth Partners LLC now owns 5,039 shares of the company’s stock worth $452,000 after purchasing an additional 382 shares in the last quarter. Longfellow Investment Management Co. LLC increased its stake in shares of Merck & Co., Inc. by 20.4% during the 1st quarter. Longfellow Investment Management Co. LLC now owns 19,376 shares of the company’s stock worth $1,739,000 after purchasing an additional 3,282 shares in the last quarter. Quilter Plc increased its stake in shares of Merck & Co., Inc. by 5.6% during the 1st quarter. Quilter Plc now owns 1,180,797 shares of the company’s stock worth $105,988,000 after purchasing an additional 62,933 shares in the last quarter. Finally, Simplicity Wealth LLC increased its stake in shares of Merck & Co., Inc. by 991.7% during the 1st quarter. Simplicity Wealth LLC now owns 33,394 shares of the company’s stock worth $2,997,000 after purchasing an additional 30,335 shares in the last quarter. 76.07% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Price Performance

Shares of Merck & Co., Inc. stock opened at $83.96 on Wednesday. Merck & Co., Inc. has a twelve month low of $73.31 and a twelve month high of $114.79. The stock has a market capitalization of $209.71 billion, a P/E ratio of 12.94, a PEG ratio of 0.81 and a beta of 0.37. The company has a current ratio of 1.42, a quick ratio of 1.17 and a debt-to-equity ratio of 0.69. The business’s fifty day moving average price is $82.55 and its 200 day moving average price is $81.71.

Merck & Co., Inc. (NYSE:MRK) last issued its earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating analysts’ consensus estimates of $2.03 by $0.10. The firm had revenue of $15.81 billion for the quarter, compared to analysts’ expectations of $15.92 billion. Merck & Co., Inc. had a return on equity of 41.05% and a net margin of 25.79%. Merck & Co., Inc. has set its FY 2025 guidance at 8.870-8.970 EPS. As a group, research analysts anticipate that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, October 7th. Investors of record on Monday, September 15th will be issued a dividend of $0.81 per share. The ex-dividend date is Monday, September 15th. This represents a $3.24 annualized dividend and a dividend yield of 3.9%. Merck & Co., Inc.’s payout ratio is presently 49.92%.

Wall Street Analyst Weigh In

A number of research analysts have recently weighed in on MRK shares. Wells Fargo & Company dropped their price objective on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an “equal weight” rating for the company in a research note on Wednesday, July 30th. Morgan Stanley dropped their price objective on shares of Merck & Co., Inc. from $99.00 to $98.00 and set an “equal weight” rating for the company in a research note on Thursday, July 10th. Finally, Berenberg Bank cut shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating and dropped their price objective for the stock from $100.00 to $90.00 in a research note on Wednesday, September 17th. One investment analyst has rated the stock with a Strong Buy rating, six have given a Buy rating, thirteen have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company currently has an average rating of “Hold” and a consensus price target of $106.41.

Merck & Co., Inc. Profile

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.